Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.255 USD | +2.71% | -2.96% | +45.56% |
May. 09 | Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 65.52M |
---|---|---|---|---|---|
Net income 2024 * | -25M | Net income 2025 * | -29M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.58
x | P/E ratio 2025 * |
-3.21
x | Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.25% |
Latest transcript on Lantern Pharma Inc.
1 day | -1.14% | ||
1 week | -11.09% | ||
Current month | +19.41% | ||
1 month | -4.69% | ||
3 months | +54.18% | ||
6 months | +61.54% | ||
Current year | +42.29% |
Managers | Title | Age | Since |
---|---|---|---|
Panna Sharma
CEO | Chief Executive Officer | 53 | 18-06-30 |
David Margrave
DFI | Director of Finance/CFO | 64 | 18-05-31 |
Reggie Ewesuedo
CTO | Chief Tech/Sci/R&D Officer | - | 23-03-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Panna Sharma
CEO | Chief Executive Officer | 53 | 18-06-30 |
Director/Board Member | 73 | 22-06-07 | |
Donald Keyser
CHM | Chairman | 71 | 17-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 6.23 | +2.30% | 21 363 |
24-05-13 | 6.09 | -1.14% | 50,748 |
24-05-10 | 6.16 | -9.54% | 236,413 |
24-05-09 | 6.81 | +5.09% | 174,869 |
24-05-08 | 6.48 | +0.93% | 56,842 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.29% | 65.52M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+43.85% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- LTRN Stock